



September 12th, 2023

**Biocon Biologics Inc.  
Notice Regarding Ogivri® & Fulphila®  
National Drug Code Numbers Update and Impact on  
340B Virtual Inventory Management**

Biocon Biologics Inc, a Biocon Biologics Limited company (“Biocon”) has asked the Office of Pharmacy Affairs (“OPA”) to post this notice on the OPA’s public website to notify 340B covered entities that the national drug code (NDC) numbers for Ogivri® (trastuzumab-dkst) and Fulphila® (pegfilgrastim-jmdb) for Injection are being transitioned to new NDCs as follows.

These NDC changes will be accompanied by product packaging changes as ownership of these products has changed from Mylan Institutional LLC, a Viartis company (“Viatris”) to Biocon Biologics Inc.

<b>Product Description</b>	<b>OLD/EXISTING NDC</b>	<b>NEW/REPLACEMENT NDC</b>	<b>WAC Price</b>
OGIVRI, 150 mg/Vial Single-Dose Vial	67457-991-15	83257-001-11	\$940.51
OGIVRI, 420 mg/Vial Multiple-Dose Vial and Bacteriostatic Water for Injection, USP	67457-847-44	83257-004-12	\$2,625.05
FULPHILA, 6 mg/0.6mL Single-Dose Prefilled Syringe	67457-833-06	83257-005-41	\$2,087.50

Biocon Biologics or your distributor will communicate further information regarding the availability of each new NDC with those new NDCs being available as early as October 1st, 2023. Old NDCs will continue to be sold through post October 1st and will continue to be available depending on the rate of purchase and pre-existing inventory levels.

The new NDCs do not signify any change in product form, strength, or composition. Biocon Biologics will treat each new NDC the same as the corresponding old NDC with respect to



pricing and purchasing from Biocon Biologics under the 340B program. Because each new OGIVRI and FULPHILA NDC represents the same product with the same 340B price as the corresponding old NDC, Biocon Biologics will permit an eligible 340B covered entity using a compliant 340B inventory replenishment model to count accumulations of each old NDC toward replenishment of equal quantities of each corresponding new NDC.

Biocon Biologics wishes to emphasize that 340B pricing for the new NDCs will remain the same as for the old NDCs.

Please see the table, below, for additional product information.

<b>Product Description</b>	<b>10-digit NDC</b>	<b>11-digit NDC</b>	<b>Pack Size</b>
OGIVRI, 150 mg/Vial Single-Dose Vial	83257-001-11	83257-0001-11	1 Vial
OGIVRI, 420 mg/Vial Multiple-Dose Vial and Bacteriostatic Water for Injection, USP	83257-004-12	83257-0004-12	1 Vial
FULPHILA, 6 mg/0.6mL Single-Dose Prefilled Syringe	83257-005-41	83257-0005-41	1 Syringe

For any questions regarding this notice contact Biocon Biologics Customer Relations at (833)-605-0806 or [GMB-SPS-BIOCON@cordlogistics.com](mailto:GMB-SPS-BIOCON@cordlogistics.com).